VITAL awards up to $250k in non-dilutive funding for six-month projects supporting academic innovators and companies developing, evaluating, and validating innovative therapeutic and vaccine solutions aligned with BARDA’s health security mission. Multi-use and platform technologies are strongly encouraged.
Are you working on groundbreaking therapeutics solutions? The VITAL Hub seeks proposals for the development of innovative therapeutics solutions in alignment with BARDA’s mission to promote health security. Multi-use/platform technologies are preferred for this solicitation. VITAL invites startups and university-backed projects to apply for non-dilutive funding of up to $250K.
We are seeking product development-focused solutions in the following topic areas:
Versatile, broad-spectrum therapeutics for the treatment of BARDA-relevant viral threats.
Mechanistic approaches may include the direct targeting of viruses or modulation of host factors. Therapeutic approaches that are considered to be in scope for this opportunity include programmable RNA antivirals including siRNA, antisense oligos and CRISPR-Cas13, decoy receptors and soluble host-factor traps, lectins, glycans and glycan-mimetic traps, host-virus interaction blockers, and broad-spectrum antiviral peptides. Molecules that are considered to be out of scope for this opportunity include monoclonal antibodies and small molecule drugs (<900 Daltons), including nucleotide and nucleoside analogues, that are being solicited under the SMART Antiviral Prize (https://vitalhubhealth.com/smart-antiviral-prize/) opportunity.
Multiple antigen scaffolds to boost vaccine efficacy against BARDA-relevant viral threats.
Of Innovative Product Development-Focused Therapeutics Solutions Aligned with BARDA’s Mission*
BARDA also recently released TPPs relevant to some of its areas of interest.
BARDA primarily develops medical countermeasures to counter acute threats and does not support research and development or acceleration in the areas of oncology or chronic disease.
However, BARDA does partner with innovators and companies developing platform and multi-use technologies. Applicants can include data from other use cases so long as BARDA funding will be used to support research and development of the BARDA-relevant use cases.
Join our mailing list to be the first to know about upcoming opportunities.
Pre-proposal applications are now closed. Please stay tuned for additional funding programs.
Applicants advancing to the next stage will be notified by November 2025 to submit a full application (by invitation only).
Winter 2025/2026 – Awardees will be selected and notified by early 2026.
Watch the latest Info Session to gain insights into the Annual Non-Dilutive Funding opportunity.
Browse common topics below, or search for a specific question to find what you need quickly.
For more information on BARDA areas of interest, visit https://www.medicalcountermeasures.gov/barda/barda-baa.
BARDA also recently released TPPs relevant to some of its areas of interest: https://medicalcountermeasures.gov/barda/tpp.
We are accepting applications from early-stage biotech companies as well as academic and other innovators globally.
We are accepting applications from early-stage biotech companies as well as academic and other innovators globally. Companies and individuals are welcome to apply for both the Accelerator Program and non-dilutive funding from VITAL. Applications will be reviewed independently. Solicitations for both the Accelerator Program and non-dilutive funding opportunities will be open on an annual basis.
No. SAM.gov registration is not required.
Applications will be evaluated with a particular focus on 1) the ability of the proposed application of the technology to support BARDA’s mission, 2) the uniqueness of the innovation and its ability to address unmet needs, and 3) the capacity for the proposed use of funds to advance the technology to the next value inflection point.
It is anticipated that project milestones will be completed in 6 months from the start of the project, and that the funding will be spent during this time period. Project management and mentor support will be provided during this 6-month period. VITAL and BARDA also understand that unforeseen and unpredicted events happen during development, evaluation and validation activities.
There will be reporting requirements on a quarterly basis, based on milestones achievement, and a final report.
Allowable expenses for the non-dilutive funds from VITAL include: direct costs for development, evaluation, or validation activities, and labor for personnel or CROs “doing the work”. Indirect costs are permitted but count toward the total cost limit, which is capped at $250K.
Companies and individuals that receive funding from VITAL will have access to BARDA subject matter experts and other related BARDA resources. Access to these BARDA resources will be managed and coordinated by the VITAL Lead Mentor.
VITAL is part of the BARDA Accelerator Network hubs. The other 4 hubs are focusing on: digital health (PARATUS), enabling technologies (BioTools Innovator VANGUARD), innovations in pediatrics (SPARK), and diagnostics and medical devices (VANTAGE). Innovators developing models for vaccines/therapeutics discovery may want to look into opportunities with the PARATUS and VANGUARD hubs in addition to VITAL, depending on the underlying technology. If your technology could significantly and specifically improve sampling, delivery, efficacy, durability, etc., of vaccines/therapeutics for pediatric populations, you may want to look into opportunities with the SPARK hub in additional to VITAL.
VITAL will not fund AMR technologies broadly under this solicitation, including diagnostics, vaccines, and antibacterial therapeutics. The one exception is antifungal drug candidates: first-in-class, broad-spectrum antifungal small molecule or peptide-based candidates for invasive fungal infections are in scope and eligible for DEV funding. If you are developing antibacterial AMR innovations, please visit the CARB-X program website to view current funding priorities: https://carb-x.org/apply/funding-themes/.
This funding opportunity does not support gain of function research or research that involves the manipulation of pathogens resulting in potential gain of function.
Proposals will be evaluated for the appropriate use of strain(s) in proposed studies.
Does your technology not fit under one of the current focus areas, but aligns with BARDA’s mission?
VITAL reviews applications on a rolling basis, and applicants are invited to submit a full proposal based on BARDA priorities and availability of funds.